Immunofusion: what changed
Two fiscal years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
Immunofusion
Largest movements
- Cash +€18,884
up €18,884 (+556.9%), from €3,391 to €22,275
mainly Other debts (+€51,313) and Trade debts (+€14,963)
- Receivables within one year +€8,486
up €8,486 (+619.4%), from €1,370 to €9,856
of which Other amounts receivable: +€7,123
- Other debts +€51,313
up €51,313 (+58.7%), from €87,478 to €138,791
- Profit (loss) carried forward -€42,606
down €42,606 (-49.3%), from -€86,443 to -€129,049
- Trade debts +€14,963
up €14,963 (+2061.1%), from €726 to €15,689
- Accrued charges and deferred income +€3,700
new in 2025: €3,700
- Gross operating margin +€30,174
up €30,174 (+41.5%), from -€72,670 to -€42,496
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Cash bridge derived
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €4,761 | €32,131 | +€27,370 | +574.9% |
| Current assets | 29/58 | €4,761 | €32,131 | +€27,370 | +574.9% |
| Amounts receivable within one year | 40/41 | €1,370 | €9,856 | +€8,486 | +619.4% |
| Trade receivables | 40 | - | €1,363 | +€1,363 | |
| Other amounts receivable | 41 | €1,370 | €8,493 | +€7,123 | +519.9% |
| Cash at bank and in hand | 54/58 | €3,391 | €22,275 | +€18,884 | +556.9% |
| Total equity and liabilities | 10/49 | €4,761 | €32,131 | +€27,370 | +574.9% |
| Equity | 10/15 | -€83,443 | -€126,049 | -€42,606 | -51.1% |
| Contributions | 10/11 | €3,000 | €3,000 | = | 0.0% |
| Profit (loss) carried forward | 14 | -€86,443 | -€129,049 | -€42,606 | -49.3% |
| Amounts payable | 17/49 | €88,204 | €158,180 | +€69,976 | +79.3% |
| Amounts payable within one year | 42/48 | €88,204 | €154,480 | +€66,276 | +75.1% |
| Trade debts | 44 | €726 | €15,689 | +€14,963 | +2061.1% |
| Suppliers | 440/4 | €726 | €15,689 | +€14,963 | +2061.1% |
| Other amounts payable | 47/48 | €87,478 | €138,791 | +€51,313 | +58.7% |
| Accrued charges and deferred income | 492/3 | - | €3,700 | +€3,700 | |
| Other operating charges | 640/8 | €118 | €0 | -€118 | -100.0% |
| Gross operating margin | 9900 | -€72,670 | -€42,496 | +€30,174 | +41.5% |
| Operating profit (loss) | 9901 | -€72,788 | -€42,496 | +€30,292 | +41.6% |
| Financial charges | 65/66B | €70 | €110 | +€40 | +57.3% |
| Recurring financial charges | 65 | €70 | €110 | +€40 | +57.3% |
| Profit (loss) for the period before taxes | 9903 | -€72,858 | -€42,606 | +€30,252 | +41.5% |
| Profit (loss) for the period | 9904 | -€72,858 | -€42,606 | +€30,252 | +41.5% |
| Profit (loss) for the period to be appropriated | 9905 | -€72,858 | -€42,606 | +€30,252 | +41.5% |
Source: filed annual accounts (NBB), fiscal years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 3 October 2026 via checked.be.